Open AccessOptimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Author(s) -
Caroline Rieser,
Mazen Zenati,
Sowmya Narayanan,
Nathan Bahary,
Kenneth K Lee,
Alessandro Paniccia,
David L. Bartlett,
Amer H. Zureikat
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-09822-1
Subject(s) - medicine , surgical oncology , neoadjuvant therapy , pancreatic cancer , oncology , general surgery , cancer , breast cancer
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort remains to be studied.